ALT - Altimmune Inc logo

ALT

Altimmune Inc

Altimmune Inc develops peptide-based therapeutics targeting serious liver diseases and obesity. Its lead candidate, pemvidutide, is in Phase 3 trials for metabolic dysfunction-associated steatohepatitis and alcohol-related liver diseases.

โš•๏ธ Healthcare NASDAQ Listed 2005 $ USD
$1,000 invested 5 years ago โ†’$248today

Score Overview

1 Year
Score
Net Growth-3.39%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-12.20%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.4
Net Growth6.19%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-99.18%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-146.98%
Net Trend40%
Net Income Consistency
Rev Growth-99.31%
Rev Trend40%
Revenue Consistency
20 Years
Score2.2
Net Growth-89x
Net Trend45%
Net Income Consistency
Rev Growth-98.05%
Rev Trend45%
Revenue Consistency
All Time
Score
Net Growth-328x
Net Trend48%
Net Income Consistency
Rev Growth-93.86%
Rev Trend48%
Revenue Consistency

See the full market ranking โ†’

Altimmune Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 8M to $ 41K and net income went from -$ 49M to -$ 88M. Revenue increased in 2 of those 5 years; net income in 2.

Across Altimmune Inc's full reported history, from 2005 to 2025, revenue declined from $ 586.07K to $ 41K and net income went from $ 277.3K to -$ 88M. Revenue increased in 48% of the years measured; net income in 48%.

Altimmune Inc currently holds a 20-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.93โ€”
1 Year2025-08-12
$ 3.62-19.06%
5 Years2021-08-12
$ 11.83-75.23%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 36K-$ 91M$ 331M
2025$ 41K-$ 88M$ 273M
2024$ 20K-$ 95M$ 131M
2023$ 426K-$ 88M$ 197M
2022-$ 68K-$ 84M$ 184M
2021$ 4M-$ 97M$ 190M
2020$ 8M-$ 49M$ 215M
2019$ 5M-$ 20M$ 37M
2018$ 10M-$ 39M$ 33M
2017$ 41.5K-$ 46M$ 8M
2016$ 5M$ 193M$ 220M
2015$ 10M-$ 3M$ 15M
2014$ 10M-$ 9M$ 18M
2013$ 17M-$ 11M$ 10M
2012$ 25M-$ 4M$ 12M
2011$ 24M-$ 3M$ 11M
2010$ 20M-$ 34M$ 11M
2009$ 27M-$ 32M$ 5M
2008$ 32M-$ 36M$ 22M
2007$ 14M-$ 13M$ 52M
2006$ 1M$ 1M$ 675.3K
IPO2005$ 586.07K$ 277.3K$ 1M

Explore beyond ALT

You're looking at Altimmune Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies